{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:11:24Z","timestamp":1760080284475,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2019,6,18]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To report four cases of new onset or exacerbation of uveitis following administration of infliximab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective observational case series includes four patients who developed new onset or exacerbation of uveitis paradoxically during infliximab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Four patients were assessed, including three women, with a mean age of 33 (14\u201384) years. Infliximab was introduced for the treatment of scleritis associated with rheumatoid arthritis (two cases), chronic anterior uveitis associated with juvenile idiopathic arthritis (JIA) (one case) and Crohn\u2019s disease (one case). Anterior scleritis associated with rheumatoid arthritis successfully improved following infliximab administration; however, macular oedema or dense vitritis paradoxically developed in two cases. In one case, infliximab was switched to tocilizumab. In another case, infliximab was discontinued, and additional corticosteroids and immunosuppressive medications were added. In one patient with JIA, new-onset macular oedema and exacerbation of anterior uveitis were observed during infliximab treatment, so the patient was switched to adalimumab. In the patient with Crohn\u2019s disease treated with infliximab, severe vasculitis and macular oedema occurred, requiring intravitreal triamcinolone injection. The patient was switched to adalimumab. Given that these reactions were paradoxical effects of infliximab, infliximab treatment was discontinued in all cases, and additional corticosteroids or immunosuppressive medications were added. All cases remained free of ocular inflammation at the last visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Uveitis rarely occurs de novo or is exacerbated during infliximab treatment. Cessation of infliximab led to resolution of this paradoxical adverse effect.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2018-000250","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:05:13Z","timestamp":1562573113000},"page":"e000250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["New onset or exacerbation of uveitis with infliximab: paradoxical effects?"],"prefix":"10.1136","volume":"4","author":[{"given":"Chiharu","family":"Iwahashi","sequence":"first","affiliation":[{"name":"Ophthalmology, Sumitomo Hospital, Osaka, Japan"},{"name":"Ophthalmology, Kindai University Faculty of Medicine Hospital, Osakasayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikari","family":"Ono","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Haruta","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Minami","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Mashimo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shimojo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-0811","authenticated-orcid":false,"given":"Nobuyuki","family":"Ohguro","sequence":"additional","affiliation":[{"name":"Ophthalmology, Japan Community Health Care Organization Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,7]]},"reference":[{"key":"2025090109374765000_4.1.e000250.1","first-page":"1100","article-title":"Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat","volume":"35","author":"de Vos","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109374765000_4.1.e000250.2","doi-asserted-by":"crossref","unstructured":"Sugita S , Kawazoe Y , Imai A , et al . Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et's disease. Arthritis Res Ther 2012;14.doi:10.1186\/ar3824","DOI":"10.1186\/ar3824"},{"key":"2025090109374765000_4.1.e000250.3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"2025090109374765000_4.1.e000250.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.06.004"},{"key":"2025090109374765000_4.1.e000250.5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","article-title":"Update upon the infection risk in patients receiving TNF alpha inhibitors","volume":"18","author":"Murdaca","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2025090109374765000_4.1.e000250.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087288"},{"key":"2025090109374765000_4.1.e000250.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.10.001"},{"key":"2025090109374765000_4.1.e000250.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.11.003"},{"key":"2025090109374765000_4.1.e000250.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"2025090109374765000_4.1.e000250.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"key":"2025090109374765000_4.1.e000250.11","doi-asserted-by":"publisher","DOI":"10.1080\/09273940600659393"},{"key":"2025090109374765000_4.1.e000250.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077370"},{"key":"2025090109374765000_4.1.e000250.13","doi-asserted-by":"crossref","unstructured":"Singla MB , Hodge DK , Moawad FJ . Infliximab-induced anterior uveitis in a patient with ulcerative Colitis. J Crohns Colitis 2015;9.doi:10.1093\/ecco-jcc\/jjv030","DOI":"10.1093\/ecco-jcc\/jjv030"},{"key":"2025090109374765000_4.1.e000250.14","doi-asserted-by":"crossref","unstructured":"Ben Abdelghani K , Slouma M , Ben Jalel W , et al . Retinal vasculitis: a novel paradoxical effect of anti-TNFalpha? BMJ 2014.","DOI":"10.1136\/bcr-2014-204909"},{"key":"2025090109374765000_4.1.e000250.15","first-page":"9","article-title":"Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Beh\u00e7et's disease","volume":"5","author":"Ueda","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"2025090109374765000_4.1.e000250.16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: a new treatment perspective","volume":"35","author":"de Fidelix","year":"2015","journal-title":"Int Ophthalmol"},{"key":"2025090109374765000_4.1.e000250.17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00417-013-2552-8","article-title":"Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis","volume":"252","author":"Schaap-Fogler","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025090109374765000_4.1.e000250.18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10875-015-0182-0","article-title":"Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response","volume":"35","author":"Talotta","year":"2015","journal-title":"J Clin Immunol"},{"key":"2025090109374765000_4.1.e000250.19","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12295"},{"key":"2025090109374765000_4.1.e000250.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"2025090109374765000_4.1.e000250.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058248"},{"key":"2025090109374765000_4.1.e000250.22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"2025090109374765000_4.1.e000250.23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000271","article-title":"Retinal vasculitis","volume":"28","author":"Rosenbaum","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2025090109374765000_4.1.e000250.24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/gene.2010.34","article-title":"Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis","volume":"11","author":"van Baarsen","year":"2010","journal-title":"Genes Immun"},{"key":"2025090109374765000_4.1.e000250.25","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.866038"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2018-000250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:37:56Z","timestamp":1756744676000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2018-000250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,7]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bmjophth-2018-000250"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2018-000250","relation":{},"ISSN":["2397-3269"],"issn-type":[{"type":"electronic","value":"2397-3269"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}